Methodology

All entries for: Atavistik Bio

March 5, 2026

Atavistik Bio

Investment

Atavistik Bio raised $160 million to advance precision allosteric small molecules for the treatment of rare diseases and precision oncology.

City: Cambridge
State: MA
Investment Amount(In Millions): $160

December 18, 2025

Atavistik Bio

Investment

Atavistik Bio raised $120 million to to advance its selective oral AKT1 inhibitor for hereditary hemorrhagic telangiectasia (HHT), a severe rare bleeding disorder.

Disease Area: Rare Diseases

Source